Table 4. Stable Disease > 6 months or Partial Response (PR) by RECIST and Characterization by Patient.
| Disease Site | Histology | Dose Level | Best Response | # of Prior Cytotoxic Regimens | Duration of Treatment (weeks) | PTEN* | PI3K Mutation | RAS Mutation | RAF Mutation |
|---|---|---|---|---|---|---|---|---|---|
| Uterus | Clear Cell Carcinoma | 5 | -39% | 3 | 36 | ND | Y | ND | N |
| Ovary | High Grade Serous | 13 | -33% | 4 | 27 | ND | N | N | N |
| Cervix | Squamous | 6 | -43% | 3 | 18 | ND | N | ND | ND |
| Ovary | High Grade Serous | 13 | -59% | 7 | 63+ | ND | N | ND | N |
| Uterus | Epithelial | 13 | -38% | 4 | 21 | P | N | N | ND |
| Ovary | High Grade Serous | 13 | -50% | 2 | 48 | ND | ND | ND | ND |
| Cervix | Squamous | 13 | -68% | 1 | 60+ | ND | ND | ND | ND |
| Peritoneum | High Grade Serous | 2 | 0% | 4 | 24 | ND | N | ND | ND |
| Ovary | High Grade Serous | 3 | -7% | 5 | 36 | ND | N | ND | ND |
| Uterus | Epithelial | 8 | Non-measurable by RECIST | 1 | 36 | ND | N | N | ND |
| Ovary | High Grade Serous | 12 | -28% | 4 | 36 | ND | ND | ND | ND |
| Fallopian Tube | Epithelial | 13 | -17% | 3 | 36 | ND | N | N | N |
| Peritoneum | High Grade Serous | 13 | -19% | 5 | 30 | ND | N | N | N |
| Uterus | Epithelial | 13 | Non-measurable by RECIST | 2 | 75+ | P | ND | N | N |
| Ovary | High Grade Serous | 13 | -29% | 6 | 24 | ND | ND | ND | ND |
Abbreviations: ND, not done; N, no; Y, yes; P, present
*
PTEN is tested by immunohistochemistry; absence of PTEN generally indicates an aberration